• Four drug candidates in the pipeline
• Potential sales of Alzheimer’s drugs run to billions
• Hyalolex heading for clinical trials

India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease.

Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has been found. However, the FDA has approved five medications to treat its symptoms. IGC is hoping to make Hyalolex the sixth. The drug works through a molecular pathway that allows low doses of THC to bind to Aβ plaques and so prevent them from aggregating on neurons. IGC has entered into a definitive license agreement (http://dtn.fm/7Xsmp) with the University of South Florida (USF), which makes IGC the exclusive licensee of the USF-developed technology that is the subject of a U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” If approved, Hyalolex could go some way to reducing the costs of treating Alzheimer’s, estimated to reach $259 billion in 2017. It should also bring IGC’s market cap in line with peer valuations that range in the hundreds of millions.

Alzheimer’s has the unwelcome distinction of being number five on the list of America’s five most deleterious diseases, after heart disease, cancer, chronic lower respiratory conditions and strokes, according to the Centers for Disease Control and Prevention (CDC). Every minute, someone new develops the condition, which takes its toll not just on those afflicted but on caregivers. The Alzheimer’s Association says that ‘35% of caregivers for people with Alzheimer’s or another dementia report that their health has gotten worse due to care responsibilities, compared to 19% of caregivers for older people without dementia”. The economic cost is also staggering and, if no cure or palliative is found soon, is expected to exceed $1 trillion by 2050.

With such high stakes, IGC’s pioneering therapy has become vitally important. Its mechanism of action uses the psychotropic component of cannabis, Δ9-tetrahydrocannabinol (THC), to inhibit the enzyme acetylcholinesterase (AChE) and prevent the aggregation of AChE-induced amyloid β-peptide (Aβ), which is the key pathological marker of Alzheimer’s disease.

Current treatments authorized for sale to the public by the U.S. Food and Drug Administration (FDA) for Alzheimer’s include donepezil, approved in 1996; galantamine (2001); rivastigmine (2000); memantine (2003); and a combination of donepezil and memantine, approved in 2014. Sales of donepezil (Aricept) reached $3.5 billion in 2009, the year before its generics were allowed market entry. Sales of rivastigmine (Exelon) have been in the hundreds of millions, exceeding $1.0 billion in 2011, and sales of memantine (Namenda) continue annually above $1.0 billion. According to Mordor Intelligence, “the global Alzheimer’s’ disease market… due to drug patent expirations in 2017 and many generics entering the market… is expected to see a declination… by the year 2017. (On the other hand), the market is anticipated to grow driven by… last-stage pipeline drugs”. They might have added “like Hyalolex.”

IGC’s pipeline also includes Natrinol, a natural substitute for Marinol, or synthetic THC, aimed at relieving nausea and vomiting while increasing appetite in patients with AIDS and cancer; Caesafin, which uses combination therapy to alleviate seizures in dogs and cats; and Serosapse, which addresses several end-points in Parkinson’s disease, including rapid eye movement (REM) sleep disorder, anxiety and dyskinesia.

For more information, visit the company’s website at www.IGCInc.us

• Director nominees include Liu Shu Juan, CEO of Shewn International Group and financial controller of Shanghai Shewn Wine Co.
• Moxian is expected to formalize joint venture agreement with Shewn International Group by end of September 2017
• Joint ventures are part of Moxian’s new strategy to enter major markets in China more quickly and at lower cost

Moxian, Inc. (NASDAQ: MOXC) will nominate seven directors to its board for shareholders at its annual meeting on September 29, 2017, in Beijing, China (http://dtn.fm/y8lBO). Among the seven is Liu Shu Juan, chief executive officer of Shewn International Group, Inc. and financial controller of Shanghai Shewn Co., Ltd., the company’s primary operator in China.

Liu has been a Moxian board member since August 2017. Moxian has an agreement of understanding with Shewn International Group, Inc., expected to be finalized by the end of September 2017, for a joint venture as part of a new marketing strategy for Moxian. The Shanghai-based company plans a series of joint ventures to enable it to penetrate key markets in China more quickly and at a lower cost. James Mengdong Tan, president and chief executive officer of Moxian, told Crystal Equity Research that he has some opportunities for 30-40 companies in the pipeline for future joint ventures.

Moxian is an integrated platform operator focused on processing digital payments and converting its Moxian+ Merchant and Moxian+ User apps to paid. It has a module on its Moxian+ Merchant platform for UnionPay, the dominant digital payment processor in China. That module makes joint ventures with Moxian attractive to other businesses.

Crystal Equity Research endorses the new joint venture strategy, citing its planned effectiveness and cost cutting in Moxian’s entry into new markets. Crystal Equity has projected that Moxian will achieve sales of $2.3 million by FY2018. It also notes that the joint venture provides Moxian with a new revenue stream, giving it a percentage of Shewn’s sales processed through the Moxian+ UnionPay app.

Additionally, the joint venture is an effective way of having Moxian gain quicker entry into new markets within China at a lower price. Crystal Equity Research said that Moxian’s cash burn rate was only $1.3 million in the quarter ended June 2017 versus $5.4 million in the prior quarter. Shewn markets fine wines in China and plans to use Moxian’s relationship and app for payments through UnionPay. It is also planning to market its wines into luxury complexes through as many as 500,000 new specialized vending machines.

For more information, visit the company’s website at www.Moxian.com

Traditions can be good, for the most part, but when new ideas and technological advancements start to make those time-honored methods of doing things easier, faster and better, those customary actions, thoughts or beliefs are bound to change with the times.

Take blockchain technology, for instance. It’s the electronic ledger used for securely recording person-to-person exchanges of cryptocurrencies like bitcoin and Ethereum. A blockchain provides a secure, open, decentralized database that uses cryptographic technology to keeps users in the loop and everyone else out. Supporters of the technology are convinced that the idea at the center of bitcoin – blockchain technology – could revolutionize industries that rely on digital record keeping.

Indeed, several industries from transportation to healthcare to online retail marketing are taking a hard look at how blockchain technology might be able to help solve some recurring efficiency and customer satisfaction problems. Danish shipping giant Maersk has partnered with IBM to utilize blockchain technology in an effort to track containers as they navigate the globe. The company hopes the technology will help solve real customer problems, reduce the cost of goods, and make global trade more accessible to emerging and developing countries, according to an article published by Forbes (http://dtn.fm/A7Dkg).

The use of blockchain technology to streamline the sharing of medical records in a secure way is also being explored in the healthcare industry. A prototype system called MedRec, under development with MIT Media Lab and Beth Israel Deaconess Medical Center in Boston, uses a private blockchain based on Ethereum (http://dtn.fm/tPq3R). It automatically keeps track of who has permission to view and change medication records, and, instead of rewarding blockchain miners with cybercurrency, miners using MedRec are given access to aggregated, anonymous data from patients’ records that can be used for epidemiological studies.

Real estate agents have some of the same problems, as they struggle with managing contracts, clients and rental inventory using “traditional” methods. One company, ATLANT, is promoting its new blockchain technology as a way to change how these transactions take place (http://dtn.fm/4rSRK). Its platform is based on peer-to-peer rental hubs, eliminating the corporate footprint and lowering fees.

Online marketplaces such as Amazon and eBay are also seeking ways to better protect sellers and buyers from hackers and fraud. Using blockchain technology could provide advantages for online retail outlets, since the system offers better security (a hacker would need to pass all the blocks on the chain to steal something), and fake products could easily be tracked down, eliminating possible counterfeits.

Blockchain technology is evolving, of course, and regulators are keen to be part of the picture. Keeping an eye on the past while stepping into the future means industry standards will inevitably follow.

• Provider of mobile payment tools
• Using social media to drive ecommerce
• Marketplace that links offline and online

A look at Nielsen’s latest Global Mobile Money Report (http://dtn.fm/C8SXf) shows that Moxian, Inc. (NASDAQ: MOXC) is in the right place at the right time. The Nielsen report shows that close to half of Chinese consumers are likely to use a mobile device to pay their bills in bars, restaurants and retail stores, a far, far higher number than in the U.S. or Europe. This revealing statistic, coupled with Moxian’s position at the nexus of online retail establishments and their brick-and-mortar counterparts, gives the tech company a bet on both ecommerce and traditional retailing. The company, based in mainland China, operates an online platform that uses the drawing power of social media to drive business to small and medium-sized enterprises (SMEs). Now, with its capability to handle mobile payments recently upgraded, Moxian is likely to see its bets on O2O commerce pay off handsomely in the near future.

Although, at present, global online sales are still only about 10 percent of overall retail sales, its trend has been ever upward. Moreover, that global average hides some eye-opening detail. While in North America and Western Europe online accounted for 7.7 percent and 8.2 percent of the overall retail market in 2016, respectively, the retail market in China is running at around 12 percent of total consumer sales, according to data reported by Deloitte (http://dtn.fm/2ldKN). In 2015, total retail sales of consumer goods in China were valued at $4.61 trillion, which puts online retail in China at around $553 billion, a mind-boggling level of exchange that surpasses the national income of 191 countries of the 211 recognized by the United Nations as sovereign states.

Already, many of these online transactions are being initiated through mobile devices, with some analysts estimating that, in China, mobile accounts for around three-quarters of all online payments. A study by the Financial Times, reported by NPR (http://dtn.fm/Q083n), says that the ‘Chinese spent $5.5 trillion through mobile payment platforms last year, about 50 times the amount in the U.S.’ So powerful is the trend to mobile in this country of 1.3 billion, some commentators are suggesting (http://dtn.fm/dSS9j) that ‘China… the first country in the world to use paper money… (may) be the first to stop. In Beijing it is hard to find a product or a service that cannot be purchased with a mobile.’

Moxian is cashing in on this cashless trend. In early 2017, the company announced the launch of a new version of its Moxian User App and Business App (New Version Apps) that feature built-in UnionPay payment modules. This follows the company’s strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay, in December 2016.

This seamless integration of Moxian’s proprietary virtual currency engine and UnionPay’s powerful payment gateway will allow users (merchants and shoppers) of the New Version Apps to process payments through UnionPay’s payment gateway, which also supports payments from Alipay and WeChat Pay. The UnionPay payment gateway also meshes seamlessly with Moxian’s MO-Coin and MO-Point system, which rewards customers who use and process payments with the New Version Apps. The Moxian Software Machine also tracks customer behavior, which in turn allows Moxian to provide the participating merchants with complete and detailed analytic data and tools. Merchants on the Moxian Marketplace can study the behavior of their customers and respond with precise targeted marketing campaigns.

Moxian is out to make smartphone payments while shopping easier for the Chinese consumer, whether buying online or at a favorite bazaar. For the merchant, the company provides access to the latest, most sophisticated marketing tools. As China ditches cash, the Moxian O2O Marketplace looks set to continue blurring the line between offline and online commerce.

For more information, visit the company’s website at www.Moxian.com

Amid a continued boom in the growing cannabis sector, Canada is moving rapidly toward legalization as the U.S. continues to foot drag at the federal level, leading many sector analysts to conclude that it’s the Canadian companies who might benefit the most as an underlying shift toward medical and recreational use continues. Out of a tiny handful of just 58 Health Canada-licensed producers, vertically integrated Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) stands out as a one of the fastest growing cultivators and pharma developers, having also obtained authorization to produce cannabis oils. While sales of dried marijuana intended for smoking in Canada increased around 44.6 percent from Q1 to Q2, according to official Health Canada records (http://dtn.fm/ypK5J), cannabis oil sales shot up over 278 percent. It’s a sustained industry trend, which is continuing to evolve as cannabis medicine developer demand increases and consumers flock to edibles and/or vaporizing. This trend is also clearly evident from U.S. data (http://dtn.fm/mx4LH), as consumers in states like Colorado, Oregon and Washington continue to fuse their love of candies and chocolates with a growing taste for cannabis.

Landmark legislation introduced by Canadian Prime Minister Trudeau in April, fulfilling one of his campaign promises, put Canada squarely on the road to a legalized (over 18) recreational use market, with a projected implementation date as early as July 1, 2018. Intelligent companies like Emblem aren’t wasting any time in trying to get out ahead of this curve and are making every effort to rapidly expand production while maintaining the kind of quality control that translates directly into end-market loyalties. For Emblem, which is focused on medical and pharmaceutical R&D, in addition to production/distribution to patients and patient/physician education via the company’s three different business segments, successful doubling of the company’s production capacity is seen as essential to ensuring long-term capacity to capture this sector’s astounding growth.

Emblem is just getting warmed up. The company recently entered into agreements to acquire some 80 acres of industrially zoned land for $7.7 million (http://dtn.fm/2lyCl), in close proximity to the existing, custom-built 23,500 sq. ft. Paris, Ontario, facility, that utilizes the latest in indoor grow science. Once completed (Q4 2018 target date), the three new state-of-the-art 100,000 sq. ft. production facilities should bring Emblem’s annual production capacity up to around 154,000 pounds. For a company that did $398,260 in sales during Q2 2017, with 118.8 pounds sold at an average price of $7.39 per gram, this new projected production figure would translate into over $516.2 million in revenues per year, not too shabby for an operation that ended Q2 with $33.0 million in cash on hand and has around another $34 million of “in-the-money” warrants (part of which is callable).

Emblem can obviously read the handwriting on the wall here and is anticipating that the dried flower and derivative products space will blossom under the new regulatory framework being spearheaded by Trudeau’s government. Emblem had 2,154 active patients as of August 24 and anticipates continued success on the strength of its marketing platform and patient registration pace. Emblem’s cannabis healthcare vertical, GrowWise Health, continues to see considerable expansion of the clinic network, driven by receptivity to the company’s comprehensive patient and physician medical cannabis education programs. The educational effort is marketing gold for Emblem, and the care taken by the company’s Patient Educators, who are knowledgeable about both healthcare and cannabis, helps a great deal when it comes to ensuring continued patient enrollment growth.

As of June of this year, there were some 201,400 client registrations (http://dtn.fm/ypK5J) with a licensed producer operating under the auspices of ACMPR (Access to Cannabis for Medical Purposes Regulations), according to Health Canada’s figures. An Ipsos poll conducted for Global News earlier this year indicated that 61 percent of Canadians now support the legalization of recreational marijuana (http://dtn.fm/1diqI), with that number being as high as 73 percent among millennials (ages 18 to 34). This polling data underscores the validity of the growing trend in Canada toward common sense cannabis regulation, which is increasingly focused on handling cannabis in the same manner as alcohol or tobacco and thus opening the door to a sizeable tax haul on what is potentially an $8.7 billion base domestic retail market (http://dtn.fm/Wt4kA).

It’s a compelling figure that underwrites how Canada is setting itself up to be a major exporter to a global market, estimated by Grand View Research as climbing to $55.8 billion by 2025 on the strength of medical alone. Troy Dayton, CEO, noted that industry analyst firm Arcview Group confirmed this outlook recently, citing medical marijuana legalization in Germany as a key indicator. With the North American market up 30 percent year-over-year to $6.7 billion in 2016 according to Arcview (http://dtn.fm/HI1Nk), running white-hot on a projected 27 percent CAGR in sales through 2021, we are looking at an estimated $20.2 billion market within a handful of years. Moreover, Arcview analysts suggest that the figure could triple as broader recreational markets come online in Canada, or in U.S. states such as California, where Proposition 64 has put the legal market for marijuana on track to exceed $5 billion.

This trend is music to Emblem’s ears, and with the new facility set up to function off natural gas infrastructure, the company has every intention of reaching for the brass ring, going “off grid” and realizing a long dreamt-of goal to become one of the lowest cost “closed box” producers in Canada. Key partnerships, such as the one signed in late 2016 with Lift Cannabis to offer a limited edition strain (“Liv by Lift”), are a solid example of why Emblem is able to command prices for certain of its carefully cultivated strains that are as high as $12.00 per gram. The company’s purpose-built Paris, Ontario, facility, featuring a Canadian-made Argus controlled system, is something to behold, and Emblem is able to legitimately pride itself to customers on the value of the company’s regulated environment indoor grow rooms, where positive pressure helps immensely in controlling external contaminants. This is mission critical stuff when it comes to commanding robust prices for product, and when it comes to meticulously cultivating and testing strains that are then rigorously tested for the targeted cannabinoids and terpenes which will provide the greatest amount of patient relief.

Emblem is hard at work identifying which of the over 100 different types of cannabinoids offer the best therapeutic values and is systematically cultivating the proper strains at medical grade in order to empower the company’s development of advanced dosage forms that are not only consistently high quality, but easy and convenient to use.

For more information, visit the company’s website at www.EmblemCorp.com

Findit, Inc. (OTC: FDIT) recently announced that its interactive social media campaign management Findit App is now available for download on iOS devices in the Apple® App Store.

“Having Apple approve our app for IOS users is one more step closer to providing anyone who wants to reach more people on the web the ability to do so,“ Findit, Inc. CEO and President Raymond Firth stated in a news release, noting that the app is also available in the Google Play Store for Android devices. “We are really pulling everyone together that has the desire to have their content seen and shared socially and indexed in search engines.”

Apple reviews all apps submitted to the App Store in an effort to ensure they are reliable, perform as expected, are free of offensive material and meet all of the company’s rigorous requirements, according to Apple’s website.

The Findit app gives everyone the ability to view and search content posted to the app or Findit.com, while Findit members can post content to an open platform available for anyone to view. Each post can be shared to social sites such as Facebook (NASDAQ: FB), Google+ (NASDAQ: GOOG), Twitter (NASDAQ: TWTR), Pinterest, LinkedIn, Tumblr and other social and bookmarking sites. Additional search results are created as posts and are shared and crawled by search engines, creating greater organic search results and social engagement.

The Findit app consists of several content verticals that can be combined into a single post, literally giving users the ability to include up to 6,000 characters in one post, an unlimited number of photos, a video, and a link for readers to click on. Anyone who posts on Twitter or Instagram, for example, can reach more people by creating the same post or a new message on Findit, where it is indexed for maximum exposure. Visitors can then be directed to other social sites or can simply view and share the message.

Individuals, organizations and companies can now reach more followers, more customers and more business simply by downloading the Findit app in the Apple Store or by going to www.Findit.com.

The Green Organic Dutchman (“TGOD”), a 100-percent owned subsidiary of The Green Organic Dutchman Holdings Ltd., produces high-quality medical marijuana. Its organic medical cannabis is farm grown and pesticide-free. There are many factors in favor of the company. The demand in a legal national market, consumer preference for organic foods and products of all kinds and a recent $20 million private placement are all positive signs. Also, TGOD is among a select group of companies licensed to cultivate medical cannabis by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Those interested in investing should contact TGOD directly at financing@tgod.ca, because the company is not yet publicly traded.

Notably, the company has gained tremendous financial support in a short time frame and began production in late 2016. Its parent holding company recently entered into an agreement with a syndicate, led by PI Financial Corp., for a brokered private placement worth $20 million. The offering of a total of 4,242,500 units, priced at C$1.65 per unit, amounts to total gross proceeds of C$7,000,125, according to a recent press release (http://dtn.fm/sEi2m). However, the amount may differ based on mutual agreement between both parties.

In addition, TGOD engaged in a concurrent, non-brokered private placement of 7,979,000 units, affording aggregate gross proceeds of over $13,000,000 (at C$1.65 per unit). Consisting of one common share of TGOD, each unit also includes a one-half common share purchase warrant for the company. A whole warrant can be exercisable into a single common share that expires 36 months after the common shares begin trading on a stock exchange, or from February 28, 2021. The warrant will be called to trade at the same time as the IPO shares, allowing investors to immediately realize the added value on the TGOD IPO. The only other free trading stock available will be the IPO shares themselves. A six-month escrow period will apply to the common shares, and a 12-month period will apply to the shares issuable once the warrants are exercised.

TGOD employs a retail first approach, allowing smaller investors to get in at these early stages not typically seen by retail investors. The specifics of this agreement are of great interest to investors. However, the company is at an advantage since both offerings will enable it to add working capital and to further develop its Ontario and Quebec cannabis facilities. Currently, it has a funded capacity of 14,000 kilograms and has one of the largest licensed parcels of land in Canada at 175 acres. The company recently purchased 75 acres for a second cannabis production facility in Quebec, which will be located in Salaberry-de-Valleyfield. This property is large enough to support 820,000 square feet of greenhouse space and increased production capacity of 116,000 kilograms annually.

Production focus is on low cost and advanced operations. The Green Organic Dutchman has partnered with Larssen Ltd., Greenhouse Engineers, and Eaton and Ledcor. In Quebec, the company is building a state-of-the-art facility with a climate-controlled environment. Independent air handling and environmental systems will be integrated for separate zones. The fully controlled environment will be able to reduce or eliminate contaminants to ensure that high-quality organic cannabis can be produced under optimal growing conditions.

An existing farm features an indoor production facility that can output 1,000 kilograms of product per year. A phase 1 expansion program will increase that farm’s annual production capacity to 14,000 kilograms. The capacity is expected to be on line by 2018. This expansion consists of a 123,000 square foot hybrid greenhouse facility with natural and LED lighting, and a second 20,000 square foot fully enclosed pharmaceutical facility. Both buildings are scheduled for construction to begin in late September or early October.

Focusing on all natural and organic principles, the company produces its medical cannabis in small batches. It expects to serve patients on a wider scale in the near future, but it is already accepting registration for its Beta Patient Program. The benefits of this program include access to more than 36 strains of organically grown, pesticide-free medical cannabis. Strains are specifically chosen for each individual patient’s needs. Other perks afford patients a guaranteed consistent product supply, priority service, and preferential pricing. One can sign up for the exclusive program by submitting the form on the company’s website.

Marijuana is already a billion-dollar industry in the country. From retail to products and services ranging from growers to lighting and testing labs, the value is expected to climb exponentially in the coming years. The trends are as enlightening for patients as they are for distributors, pharma companies and dispensaries. Investors in the market stand to benefit as well. Management of The Green Organic Dutchman has already invested over $5 million in the company. Notably, the company’s initial entry into the wholesale market in 2017 will yield an instant revenue stream. Production is anticipated to increase in 2018, and product is expected to be sold at a premium price given its high quality and preferred organic production.

The leadership team of TGOD includes CEO and Director Rob Anderson. He has worked in finance for 22+ years and, specifically, in the Canadian brokerage industry for 12 years financing hundreds of micro-cap companies. A record of successes has been realized through a unique identification and selection process and with multiple companies exceeding $1 billion in market valuations. Anderson has also strongly advocated for retail shareholders and supports a staged financing approach that appeals to management and addresses the capital requirements of companies.

Chairman of the Board Jeff Paikin is active in the building industry, while Director Ian Wilms brings 25 years of business experience while working with IBM and as President of the Canadian Association of Police Boards. Scott Skinner, Cofounder/Director/COO, was directly involved in the design and engineering of the company’s production facility, while Csaba Reider, President, joined TGOD from the Consumer Packaged Goods industry, hailing from Cott Beverages and Xyience Energy Drinks. The company also added Marc Bertrand as a Director, a Consumer Products executive responsible for growing and selling Mega Bloks for over $500 million dollars.

The Green Organic Dutchman is therefore built on strong leadership with a strong ability to raise capital, significant world class alliance partners, a premium priced, high quality pesticide-free organic product, one of the lowest cost production facilities in Canada, one of the largest land packages and a demand for a product that will only increase.

For more information, visit the company’s website at www.TGOD.ca

• Company has, to date, raised $41.5 million and has more than 2,400 shareholders
• Has one of the largest licensed land parcels in Canada, situated on 100 acres
• Offers organically grown, pesticide-free medical marijuana under Canada’s ACMPR

The Green Organic Dutchman Holdings Ltd. (“TGOD”), a Canadian company engaged in producing farm-grown, high-quality organic medical cannabis using craft growing, all natural, organic principles, announced on September 11 (http://dtn.fm/8GkWq) that it has entered into an agreement with a syndicate led by PI Financial Corp. to complete a private placement offering of units. The syndicate will offer, on a commercially reasonable effort basis, 4,242,500 units of the company at an issue price of C$1.65 per unit for aggregate gross proceeds of C$7,000,125.

TGOD will also concurrently engage in a non-brokered offering of 7,879,000 units, with each unit being offered at C$1.65 for aggregate gross proceeds of $13,000,350, under the same terms as the unit offering.

Each unit will consist of one common share of TGOD and one-half common share purchase warrant of the company. Each whole warrant is exercisable into one common share at the exercise price of $3.00 per share and has an expiration date that is either 36 months from the date the common shares begin trading on a recognized stock exchange or February 28, 2021, whichever is earlier.

TGOD plans to use the net proceeds of the unit offering and the non-brokered offering to advance its cannabis facilities in Ontario and Quebec, as well as for general working capital purposes.

A private producer of high-grade, organically grown and pesticide-free medical cannabis under the ACMPR, TGOD grows its marijuana in small batches, and its products are laboratory tested to ensure all recipient patients are provided with a standardized, safe and consistent product.

TGOD has a funded capacity of 14,000 kg and has one of the biggest licensed land parcels in Canada, situated on 100 acres. The company also recently secured a second 75-acre, fully serviced site near Montreal and is currently in the process of expanding its cultivation capacity to 116,000 kg and increasing its product offerings preparatory to recreational cannabis use becoming federally legal in Canada in 2018—something the Canadian government is currently making strides toward.

To date, TGOD has raised $41.5 million and has more than 2,400 shareholders.

For more information, visit the company’s website at www.TGOD.ca

• Producer of consistent, standardized medicinal cannabis
• Menu of cannabis strains with varying CBD:THC ratios
• ABcann’s CBD-Med is one of Canada’s highest-CBD products

In an interview with Cantech Letter (http://dtn.fm/5Deu5), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis for pain relief or other medical purposes, this was causing a great deal of concern.

Inconsistency in product quality makes the determination of optimal dosage levels impossible to achieve. As a result, “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on” became one of ABcann’s founding principles. That principle continues to guide the company to this day. The Canadian-licensed producer recently announced the release of one of Canada’s highest legal CBD:THC ratio cannabis products. This new product expands the range of therapies now available to patients and so increases the efficacy of current treatment regimens in the promising new field of cannabinoid therapies.

At present, the majority of cannabinoid therapies are directed to alleviate the chronic pain resulting from a variety of maladies. Since delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the cannabinoids occurring at the highest concentrations in cannabis, the therapeutic effects of the plant and its derivatives are most likely derived from these components acting alone or together.

This is a line of research that has been explored successfully by GW Pharmaceuticals. The European company produces Sativex, a treatment for the relief of symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS), which contains a one-to-one ratio of THC to CBD. While many patients have found relief from pain in high-THC cannabis, a subset of these have reported short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks. Fortunately, CBD is devoid of such malignant manifestations, exhibiting calming and uplifting properties that appear to mitigate the unwanted effects of THC. As a result, strains of cannabis that are rich in CBD, like those produced by ABcann, are most helpful to those averse or intolerant to THC and to patients who want pain relief without too much of a ‘high’.

A look at the stats released by Health Canada will show where ABcann is on the CBD:THC ratio spectrum. Most cannabis strains (54%) on the Canadian market have a high CBD:THC ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD under 1%. Only 14% of strains have both THC and CBD levels that exceed 5%, and just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which the latest ABcann strains can be found.

Late last month, the company announced (http://dtn.fm/bAJw6) the release of its top-of-the-line CBD-Med, which has a ratio of 27.6:1 (18.5% CBD to 0.67% THC). This adds to ABcann current lineup of high-CBD products, which already include NC:Med, with 18.9% CBD to 1% THC and DC:Med, with 15.4% CBD to 1% THC. ABcann also expects to be able to sell oils from October 2017, a range that will include a 1:1 THC/CBD drop, a high THC dropper and a high CBD dropper.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board

• Greenkraft, Inc. expects to realize well over $1 million of new revenue in 2017
• Expansion plans include construction of larger manufacturing facility to accommodate increasing demand for Greenkraft’s alternative fuel commercial trucks
• A new line of larger, heavy duty G3 and G4 commercial trucks are coming soon
• Greenkraft vehicles meet EPA and CARB emission standards through use of clean alternative fuels

Greenkraft, Inc. (OTCQB: GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company’s mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft’s new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

“Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel,” Gemayel states in a press release. “The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company’s revenue in 2017.”

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client’s specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation’s largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners.

For more information, visit the company’s website at www.GreenkraftInc.com

Let us hear your thoughts: Greenkraft, Inc. Message Board